Treatment exposure and reasons for discontinuation in integrated safety analysis
| . | Ibrutinib (N = 330) . |
|---|---|
| Treatment exposure | |
| Exposure, median (range), mo | 29.0 (0.2-42.9) |
| Duration of treatment, mo | |
| ≤6 | 32 (10) |
| >6 to 12 | 18 (5) |
| >12 to 24 | 34 (10) |
| >24 to 36 | 193 (58) |
| >36 | 53 (16) |
| Treatment discontinuation | 124 (38) |
| PD | 52 (16) |
| AE | 37 (11) |
| Death | 18 (5) |
| Physician decision | 9 (3) |
| Withdrawal by patient | 8 (2) |
| . | Ibrutinib (N = 330) . |
|---|---|
| Treatment exposure | |
| Exposure, median (range), mo | 29.0 (0.2-42.9) |
| Duration of treatment, mo | |
| ≤6 | 32 (10) |
| >6 to 12 | 18 (5) |
| >12 to 24 | 34 (10) |
| >24 to 36 | 193 (58) |
| >36 | 53 (16) |
| Treatment discontinuation | 124 (38) |
| PD | 52 (16) |
| AE | 37 (11) |
| Death | 18 (5) |
| Physician decision | 9 (3) |
| Withdrawal by patient | 8 (2) |
Unless otherwise noted, all data are n (%).